Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for AdaptHealth (AHCO) over the last 8 years, with Q3 2025 value amounting to $46.8 million.

  • AdaptHealth's Change in Accured Expenses rose 41518.54% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 2129.43%. This contributed to the annual value of $33.8 million for FY2024, which is 1739.23% down from last year.
  • Latest data reveals that AdaptHealth reported Change in Accured Expenses of $46.8 million as of Q3 2025, which was up 41518.54% from $60.4 million recorded in Q2 2025.
  • In the past 5 years, AdaptHealth's Change in Accured Expenses registered a high of $110.3 million during Q2 2024, and its lowest value of -$68.1 million during Q2 2023.
  • For the 5-year period, AdaptHealth's Change in Accured Expenses averaged around $2.4 million, with its median value being $3.5 million (2024).
  • As far as peak fluctuations go, AdaptHealth's Change in Accured Expenses plummeted by 47383.57% in 2021, and later soared by 72475.51% in 2022.
  • AdaptHealth's Change in Accured Expenses (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 724.76% to $9.6 million in 2022, then surged by 576.79% to $64.7 million in 2023, then plummeted by 94.59% to $3.5 million in 2024, then soared by 1236.93% to $46.8 million in 2025.
  • Its Change in Accured Expenses stands at $46.8 million for Q3 2025, versus $60.4 million for Q2 2025 and $4.5 million for Q1 2025.